布鲁菌病患者血清IL-1Ra、IL-1β的监测意义  

Significance of monitoring serum IL-1Ra and IL-1βin patients with brucellosis

作　　者：马洁 张扬 赵伊婷[1] 汤新乐 张裕祥[1] 李茜[1] MA Jie;ZHANG Yang;ZHAO Yi-ting;TANG Xin-le;ZHANG Yu-xiang;LI Qian(Clinical Laboratory,the Sixth Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830000,China)

机构地区：[1]新疆医科大学第六附属医院检验科,新疆乌鲁木齐830000

出　　处：《中国国境卫生检疫杂志》2022年第6期506-508,共3页Chinese Journal of Frontier Health and Quarantine

基　　金：新疆维吾尔自治区自然科学基金项目(2020D01C193)。

摘　　要：目的探讨监测布鲁菌病患者血清白细胞介素1受体拮抗剂(IL-1Ra)、白细胞介素-1β(IL-1β)的意义。方法选取2019年6月—2021年6月新疆医科大学第六附属医院收治的94例布鲁菌病患者,比较急性和慢性患者治疗前后血清IL-1Ra、IL-1β水平及IL-1Ra/IL-1β,并比较治疗有效和无效患者血清IL-1Ra、IL-1β水平及IL-1Ra/IL-1β。结果治疗前,急性患者血清IL-1Ra水平及IL-1Ra/IL-1β分别为(817.85±138.66)ng/L、(18.79±3.27),均低于慢性患者,差异有统计学意义(P<0.05);治疗前,急性患者IL-1β水平为(43.52±7.37)ng/L,高于慢性患者[(38.96±6.69)ng/L],差异有统计学意义(P<0.05)。治疗1个月后,急性患者血清IL-1Ra水平及IL-1Ra/IL-1β分别为(1153.62±192.35)ng/L、(55.38±9.69),均低于慢性患者[(1304.77±211.59)ng/L、(75.12±13.26)](P<0.05);治疗1个月后,急性患者IL-1β水平为(20.83±3.51)ng/L,高于慢性患者[(17.37±2.84)ng/L],差异有统计学意义(P<0.05)。急性患者治愈率为30.19%,好转率为47.17%,慢性患者治愈率为29.27%,好转率为46.34%,急性和慢性患者治疗效果差异无统计学意义(P>0.05)。结论监测布鲁菌病患者血清IL-1Ra、IL-1β水平可反映病情及状况疗效。Objective To explore the surveillance significance of interleukin-1 receptor antagonist(IL-1Ra)and interleukin-1β(IL-1β)in patients with brucellosis.Methods A total of 94 patients with acute or chronic brucellosis admitted to the Sixth Affiliated Hospital of Xinjiang Medical University from June 2019 to June 2021 were selected.The levels of serum IL-1Ra,IL-1βand IL-1Ra/IL-1βof patients with acute or chronic brucellosis before and after treatment were compared,the serum levels of IL-1Ra,IL-1βand IL-1Ra/IL-1βin patients with effective and ineffective treatments were compared.Results Before treatment,the serum levels of IL-1Ra and IL-1Ra/IL-1βin patients with acute brucellosis were(817.85±138.66)ng/L and(18.79±3.27),respectively,which were lower than those in patients with chronic brucellosis[(902.91±157.43)ng/L,(23.18±4.12)](P<0.05).Before treatment,the serum IL-1βlevel in patients with acute brucellosis was(43.52±7.37)ng/L,which was higher than that in patients with chronic brucellosis[(38.96±6.69)ng/L](P<0.05).After 1 month of treatment,the serum IL-1Ra and IL-1Ra/IL-1βof patients with acute brucellosis were(1153.62±192.35)ng/L and(55.38±9.69),respectively,which were lower than those of chronic brucellosis[(1304.77±211.59)ng/L,(75.12±13.26)](P<0.05).After 1 month of treatment,the serum IL-1βlevel in patients with acute brucellosis was(20.83±3.51)ng/L,which was higher than chronic patients[(17.37±2.84)ng/L](P<0.05).The cure rate of acute patients was 30.19%,the improvement rate was 47.17%,and the cure rate of chronic patients was 29.27%,the improvement rate was 16.34%,there was no significant difference in the treatment effect between acute and chronic patients(P>0.05).Conclusion Clinical monitoring of serum IL-1Ra and IL-1βlevels in patients with acute and chronic brucellosis can reflect the condition of the disease status and treatment effects.

关 键 词：布鲁菌病 白细胞介素1受体拮抗剂 白细胞介素 

分 类 号：R516.7[医药卫生—内科学]